top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/hCTLA4 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Ctla4tm1(CTLA4)Bcgen/Bcgen
Common Name  B-hPD-1/hCTLA4 mice
Background C57BL/6 Catalog number  120519
Related Genes 
PD-1 (Programmed death-1) ;
CTLA4 
(Cytotoxic T-lymphocyte-associated protein 4,CD152)
NCBI Gene ID
18566,12477

mRNA expression analysis


from clipboard


Strain specific analysis of PD-1 and CTLA4 gene expression in WT and hPD-1/hCTLA4 mice by RT-PCR. Mouse Pd-1 and Ctla4 mRNA were detectable only in splenocytes of wild-type (+/+) mice. Human PD-1 and CTLA4 mRNA were detectable only in H/H, but not in +/+ mice. 


Protein expression analysis




Strain specific PD-1 and CTLA4 expression analysis in homozygous B-hPD-1/hCTLA4 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hCTLA4 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1 and anti-CTLA4 antibody. Mouse PD-1 and CTLA4 were detectable in WT mice. Human PD-1 and CTLA4 were exclusively detectable in homozygous B-hPD-1/hCTLA4 but not WT mice.

Combination therapy of anti-human PD-1 antibody and anti-human CTLA4 antibody


Antitumor activity of anti-human PD-1 antibody combined with anti-human CTLA4 antibody in B-hPD-1/hCTLA4 mice. (A) Anti-human PD-1 antibody combined with anti-human CTLA4 antibody inhibited MC38 tumor growth in B-hPD-1/hCTLA4 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hCTLA4 mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with pembrolizumab and ipilimumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab and ipilimumab shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCTLA4 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hCTLA4 antibodies. Values are expressed as mean ± SEM.